Skip to main content

Table 2 Baseline characteristics of the 9 patients with hereditary hemorrhagic telangiectasia (HHT) with ascertained SarsCov-2 infection

From: Characterization of epidemiological distribution and outcome of COVID-19 in patients with hereditary hemorrhagic telangiectasia: a nationwide retrospective multi-centre study during first wave in Italy

ID Gender Age Residency region (province) HHT type PCR-based molecular diagnosis on swab sample Nasopharyngeal/oropharyngeal swab Serol. test
4 F 41 Lombardy (Bergamo) HHT2 Apparently Negative, but Molecular test was performed three months after symptom onset Nasal Pos
20 M 46 Lombardy (Bergamo) HHT2 Positive Nasal Pos
22 M 44 Lombardy (Bergamo) HHT2 Positive Nasal Pos
24 M 57 Liguria (Savona) HHT2 Positive Nasal/Oral Pos
34 F 38 Lombardy (Bergamo) HHT1 Molecular test never performeda / Pos
39 F 35 Lombardy (Cremona) HHT1 Apparently Negative, but molecular test was performed two months after symptom onset Nasal/Oral Pos
49 M 41 Lombardy (Bergamo) HHT2 Apparently Negative, but molecular test was performed two months after symptom onset Nasal Pos
66 M 49 Lombardy (Bergamo) HHT2 Molecular test never performeda / Pos
119 M 65 Lombardy (Brescia) HHT1 Positive Nasal/Oral Pos
  1. HHT1 hereditary hemorrhagic telangiectasia type 1, HHT2 hereditary hemorrhagic telangiectasia type 2, PCR polymerase chain reaction
  2. aSymptom onset occurring before lockdown/pandemic declaration, when routinely molecular assay on swab sample was not established